[1]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165-167.[doi:10.3969/j.issn.1006-1959.2022.09.042]
 XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(09):165-167.[doi:10.3969/j.issn.1006-1959.2022.09.042]
点击复制

达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年09期
页码:
165-167
栏目:
药物与临床
出版日期:
2022-05-01

文章信息/Info

Title:
Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control
文章编号:
1006-1959(2022)09-0165-03
作者:
徐晨曦
(天津蓟州区人民医院综合内科,天津 301900)
Author(s):
XU Chen-xi
(Department of General Medicine,Tianjin Jizhou District People’s Hospital,Tianjin 301900,China)
关键词:
2型糖尿病血糖控制不佳二肽基肽酶4抑制剂二甲双胍达格列净
Keywords:
Type 2 diabetes mellitusPoor blood sugar controlDipeptidyl peptidase 4 inhibitorMetforminDapagliflozin
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2022.09.042
文献标志码:
A
摘要:
目的 探究达格列净联合二肽基肽酶 4(DPP-4)抑制剂与二甲双胍对血糖控制不佳2型糖尿病(T2DM)患者血糖水平及血尿酸指标的影响。方法 选取2019年3月-2021年3月我院收治的98例血糖控制不佳T2DM患者,按照随机数字表法分为对照组与观察组,各49例。对照组给予DPP-4抑制剂联合二甲双胍治疗,观察组则在其基础上加用达格列净治疗,比较两组血糖指标[糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2h血糖(2hPBG)]、胰岛功能[空腹胰岛素(FINS)、胰岛素抵抗指数(HOMA-IR)、胰岛素分泌指数(HOMA-β)]、脂质代谢相关指标[收缩压(SBP)、舒张压(DBP)、三酰甘油(TG)、血尿酸(UA)]、血糖控制达标率、低血糖发生率。结果 两组HbA1c、FPG、2hPBG均低于治疗前,且观察组低于对照组(P<0.05);两组FINS、HOMA-β均高于治疗前,HOMA-IR低于治疗前,且观察组FINS、HOMA-β高于对照组,HOMA-IR低于对照组(P<0.05);观察组SBP、DBP、TG、UA低于治疗前,且低于对照组(P<0.05);观察组血糖控制达标率高于对照组(P<0.05);两组低血糖发生率比较,差异无统计学意义(P>0.05)。结论 达格列净联合DPP-4抑制剂与二甲双胍在血糖控制不佳T2DM患者中具有较好的控糖效果,可改善胰岛功能,降低其血糖、血压及血尿酸水平,且低血糖风险低。
Abstract:
Objective To explore the effect of daglitazone combined with dipeptidyl peptidase 4 (DPP-4) inhibitor and metformin on blood glucose level and serum uric acid index in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control.Methods A total of 98 patients with T2DM with poor glycemic control admitted to our Hospital from March 2019 to March 2021 were selected and randomly divided into control group and observation group, with 49 cases in each group. The control group was treated with DPP-4 inhibitor combined with metformin, while the observation group was treated with dagligent on the basis of the control group. The blood glucose indexes [glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPBG)], islet function [fasting insulin (FINS), insulin resistance index (HOMA-IR), insulin secretion index (HOMA-β)], lipid metabolism related indexes [systolic blood pressure (SBP), diastolic blood pressure (DBP), triglyceride (TG), and blood uric acid (UA)], blood glucose control compliance rate, and incidence of hypoglycemia were compared between the two groups.Results The HbA1c, FPG and 2hPBG of the two groups were lower than those before treatment, and those in the observation group was lower than the control group(P<0.05). FINS and HOMA-β in the two groups were higher than those before treatment, HOMA-IR was lower than that before treatment, and FINS and HOMA-β in the observation group were higher than those in the control group, HOMA-IR was lower than that in the control group(P<0.05). SBP, DBP, TG and UA in the observation group were lower than those before treatment, and lower than those in the control group(P<0.05). The compliance rate of blood glucose control in the observation group was higher than that in the control group(P<0.05). There was no significant difference in the incidence of hypoglycemia between the two groups (P>0.05).Conclusion Dagliptin combined with DPP-4 inhibitor and metformin has good glycemic control effect in patients with T2DM with poor glycemic control, which can improve islet function, reduce blood glucose, blood pressure and blood uric acid levels, and have low risk of hypoglycemia.

参考文献/References:

[1]黄霄,郝兆虎,马菲.二甲双胍联合二肽基肽酶4抑制剂治疗未达标的2型糖尿病患者应用格列喹酮的疗效研究[J].中国实用内科杂志,2021,41(2):129-132.[2]Sa-Nguanmoo P,Tanajak P,Kerdphoo S,et al.SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats[J].Toxicology and Applied Pharmacology,2017,333:43-50.[3]戚蓓蓓,宋文春,江冬梅,等.二肽基肽酶-4抑制剂西格列汀联合二甲双胍治疗2型糖尿病的疗效[J].江苏医药,2016,42(15):1728-1729.[4]梁宇,焦秀敏,张星光,等.达格列净对超重2型糖尿病患者脂联素水平和体脂分布及骨矿含量的影响研究[J].中国全科医学,2021,24(21):2655-2660,2668.[5]何瑛.二肽基肽酶4抑制剂联合地特胰岛素治疗血糖控制不佳的2型糖尿病的疗效及对血糖和氧化应激指标的影响[J].中国基层医药,2021,28(5):715-719.[6]罗琼,徐文光,李琴,等.GLP-1RA、DPP-4抑制剂治疗2型糖尿病肥胖患者的疗效及其对心血管疾病发病风险的对比[J].心血管康复医学杂志,2021,30(2):159-164.[7]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.[8]徐爱花,黄建胜,何银辉,等.达格列净片治疗2型糖尿病血糖控制不佳患者的疗效与低血糖风险观察[J].中华全科医学,2020,18(9):1500-1503,1526.[9]高芳芳,张萍,钟兴,等.达格列净对血糖控制不佳的2型糖尿病患者血糖波动的影响[J].山东医药,2020,60(14):48-50.[10]Dekkers CCJ,Petrykiv S,Laverman GD,et al.Effects of the SGLT‐2 inhibitor dapagliflozin on glomerular and tubular injury markers[J].Diabetes,Obesity and Metabolism,2018,20(8):1988-1993.[11]袁伟杰,管昊晨.钠-葡萄糖协同转运蛋白2抑制剂的肾脏获益:从理论到临床实践[J].肾脏病与透析肾移植杂志,2021,30(2):148-149.[12]曲建昌,弓月,王彤,等.达格列净联合二肽基肽酶4抑制剂和二甲双胍治疗血糖控制不佳2型糖尿病的效果分析[J].中国医药,2021,16(6):857-860.[13]邓宁,胡庆芬,梁彩虹,等.达格列净片联合盐酸二甲双胍对2型糖尿病患者的临床研究[J].中国临床药理学杂志,2019,35(18):2016-2018,2039.[14]李玉红,邵爽,孟旭英.二肽基肽酶4抑制剂维格列汀联合胰岛素治疗2型糖尿病的疗效及对超敏C反应蛋白影响的观察[J].中国糖尿病杂志,2019,27(9):658-661.[15]阳皓,谭巧灵,王岑,等.达格列净对早期2型糖尿病肾病患者尿微量白蛋白和促炎症因子的影响[J].华中科技大学学报(医学版),2019,48(4):400-404.[16]甄霞,顾红燕,文祯,等.达格列净联合胰岛素治疗特定2型糖尿病住院患者的疗效与安全性分析[J].中国医院药学杂志,2019,39(4):385-389.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
 HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(09):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
 DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(09):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
 CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(09):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
 JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(09):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
 LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]刘静波,黄 萍,赵 静.应用微信平台对初发中青年2型糖尿病患者进行 健康管理模式的研究[J].医学信息,2018,31(14):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
 LIU Jing-bo,HUANG Ping,ZHAO Jing.Study on the Health Management Model of Young and Middle-aged Patients with Type 2 Diabetes Mellitus by WeChat Platform[J].Medical Information,2018,31(09):98.[doi:10.3969/j.issn.1006-1959.2018.14.028]
[7]丁 星,赵 畅,张海严,等.麦邦数据远程传输型血糖仪临床测量准确性的评价研究[J].医学信息,2018,31(15):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
 DING Xing,ZHAO Chang,ZHANG Hai-yan,et al.Evaluation of Accuracy of Clinical Measurement of Maibang Remote Data Transmission Glucometer[J].Medical Information,2018,31(09):64.[doi:10.3969/j.issn.1006-1959.2018.15.020]
[8]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
 LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(09):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[9]刘小红.长效胰岛素联合口服降糖药治疗2型糖尿病的 疗效与安全性评价[J].医学信息,2018,31(18):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
 LIU Xiao-hong.Efficacy and Safety of Long Acting Insulin Combined with Oral Hypoglycemic Agents in Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2018,31(09):121.[doi:10.3969/j.issn.1006-1959.2018.18.038]
[10]鲍 哲,杨升伟,柯赛赛,等.益生元对2型糖尿病患者糖脂代谢的影响[J].医学信息,2018,31(18):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]
 BAO Zhe,YANG Sheng-wei,KE Sai-sai,et al.Effect of Prebiotics on Glucose and Lipid Metabolism in Patients with Type 2 Diabetes mellitus[J].Medical Information,2018,31(09):132.[doi:10.3969/j.issn.1006-1959.2018.18.042]

更新日期/Last Update: 1900-01-01